Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The Escherichia coli K88ab antigen, also known as F4ab, is a filamentous fimbrial adhesin expressed by enterotoxigenic Escherichia coli (ETEC) [PMID: 15505004]. It plays a pivotal role in the pathogenesis of porcine enteric diseases by mediating the attachment of bacteria to specific receptors on the intestinal brush border [PMID: 25103148]. This colonization is essential for the subsequent delivery of enterotoxins that cause neonatal and post-weaning diarrhea [PMID: 16439311]. The K88ab variant is one of three major serotypes (ab, ac, and ad) and is composed primarily of the FaeG major subunit, which determines its binding specificity [UniProt: P02971]. In veterinary medicine, this antigen is a key component of vaccines designed to elicit protective antibodies that block bacterial adhesion [PMID: 18466615]. Therapeutic approaches targeting K88ab include the development of oral vaccines, egg yolk-derived antibodies, and competitive carbohydrate decoys to prevent infection [PMID: 22100218].
Induction of neutralizing antibodies to prevent bacterial attachment to host intestinal receptors; competitive inhibition of adhesion.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Escherichia coli K88ab fimbrial adhesin (K88ab).